Cargando…

Hypoxia promotes stem cell-like phenotype in multiple myeloma cells

Detalles Bibliográficos
Autores principales:	Muz, B, de la Puente, P, Azab, F, Luderer, M, Azab, A K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315888/ https://www.ncbi.nlm.nih.gov/pubmed/25479569 http://dx.doi.org/10.1038/bcj.2014.82

Ejemplares similares

MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma
por: de la Puente, P, et al.
Publicado: (2016)

Molecularly Targeted Therapies in Multiple Myeloma
por: de la Puente, Pilar, et al.
Publicado: (2014)

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
por: Muz, Barbara, et al.
Publicado: (2017)

Spotlight on ixazomib: potential in the treatment of multiple myeloma
por: Muz, Barbara, et al.
Publicado: (2016)

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib
por: Muz, Barbara, et al.
Publicado: (2015)

The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
por: Muz, Barbara, et al.
Publicado: (2015)

Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination
por: Sahin, I, et al.
Publicado: (2014)

A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma
por: Alhallak, Kinan, et al.
Publicado: (2021)

E-selectin-targeting lipid nanoparticles improve therapeutic efficacy and reduce side effects of bortezomib in multiple myeloma
por: Maksimos, Mina, et al.
Publicado: (2023)

Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy
por: Muz, Barbara, et al.
Publicado: (2019)

Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma
por: Srour, Samer A., et al.
Publicado: (2021)

Tumor-associated macrophages in multiple myeloma: advances in biology and therapy
por: Sun, Jennifer, et al.
Publicado: (2022)

Multiple Myeloma Involving Skin and Pulmonary Parenchyma after Autologous Stem Cell Transplantation
por: Yuan, Yuan, et al.
Publicado: (2009)

Is There an Optimal Timing of Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Agents?
por: Toprak, Selami Koçak
Publicado: (2013)

Real-word data on autologous stem cell transplantation in older patients with multiple myeloma
por: Schain, Frida, et al.
Publicado: (2019)

Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma
por: Federico, Cinzia, et al.
Publicado: (2020)

Renal cell carcinoma concomitant with multiple myeloma
por: Narwal, Anubhav, et al.
Publicado: (2022)

Therapy-related Myelodysplastic Syndrome after Autologous Stem Cell Transplantation Using Plerixafor for Mobilized Stem Cells in a Patient with Multiple Myeloma
por: Tanaka, Hiroaki, et al.
Publicado: (2018)

β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma
por: Nair, Remya, et al.
Publicado: (2022)

Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma
por: Sun, Jennifer, et al.
Publicado: (2020)

Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells
por: Stefka, A T, et al.
Publicado: (2016)

Multiples aberrant phenotypes in multiple myeloma patient expressing CD56(-), CD28(+),CD19(+)
por: Leite, Luiz Arthur Calheiros, et al.
Publicado: (2012)

Emergence of chronic myeloid leukemia following autologous stem cell transplantation in a young woman with multiple myeloma
por: Barrett, Aisling, et al.
Publicado: (2018)

Higher cyclophosphamide dose grants optimal stem cell collection after daratumumab-based induction in multiple myeloma
por: Liberatore, Carmine, et al.
Publicado: (2023)

Bone marrow‐derived mesenchymal stem cells inhibit NK cell function via Tim‐3/galectin‐9 in multiple myeloma patients
por: Liu, Zhao‐Yun, et al.
Publicado: (2023)

Increased TOX expression associates with exhausted T cells in patients with multiple myeloma
por: Zhao, Yujie, et al.
Publicado: (2022)

Multiple Myeloma and Alkaline Phosphatase
por: Yavaşoğlu, İrfan, et al.
Publicado: (2015)

An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma
por: Darawshi, Odai, et al.
Publicado: (2022)

Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation
por: Roy, V, et al.
Publicado: (2015)

Evolving therapeutic role of bisphosphonates in multiple myeloma
por: Ural, A U, et al.
Publicado: (2005)

Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
por: Alhallak, Kinan, et al.
Publicado: (2021)

Single‐cell RNA sequencing infers the role of malignant cells in drug‐resistant multiple myeloma
por: Wang, He‐nan, et al.
Publicado: (2021)

Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients
por: Yousef, S, et al.
Publicado: (2015)

Chemerin is elevated in multiple myeloma patients and is expressed by stromal cells and pre-adipocytes
por: Westhrin, Marita, et al.
Publicado: (2018)

Carbamazepine and Multiple Myeloma: Possible Interaction
por: Günaldı, Meral, et al.
Publicado: (2013)

Daratumumab in dialysis-dependent multiple myeloma
por: Jeyaraman, Preethi, et al.
Publicado: (2020)

Targeting B-cell maturation antigen increases sensitivity of multiple myeloma cells to MCL-1 inhibition
por: Cuenca, Marta, et al.
Publicado: (2021)

Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines
por: Maura, F, et al.
Publicado: (2018)

CD155/TIGIT signalling plays a vital role in the regulation of bone marrow mesenchymal stem cell–induced natural killer–cell exhaustion in multiple myeloma
por: Liu, Zhao‐Yun, et al.
Publicado: (2022)

Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients
por: Bera, T K, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6vj6a17e946q8pd2co5aro81ac